Pathophysiology of Urinary Tract Obstruction
Pathophysiology of Urinary Tract Obstruction
Pathophysiology of Urinary Tract Obstruction
Obstruction
Jamie Bartley D.O.
PGY 3..almost 4
5/27/09
MSU-COM Metro Detroit Urology
Outline
• I. Background
• II. Pathophysiology and pathological
changes with urinary tract obstruction
• III. Patient work-up and management
• IV. Causes of urinary tract obstruction
Definitions
• Hydronephrosis- Dilation of the renal
pelvis or calyces
• Obstructive uropathy- functional or
anatomic obstruction of urine flow at
any level of the urinary tract
• Obstructive nephropathy- when
obstruction causes function or anatomic
renal damage
Prevalence
• 3.1% in autopsy series
• No gender differences until 20 years
– Females more common 20-60
– Males more common older than 60
• Renal US
– Safe in pregnant and pediatric patients
– Good initial screening test
– No need for IV contrast
– May have false negative in acute obstruction (35%)
– Hydronephrosis= anatomic diagnosis
• Can have caliectasis or pelviectasis in an unobstructed
system
– Doppler- measures renal resistive index (RI), an
assessment of obstruction
• RI= (PSV-EDV)/PSV
– RI > 0.7 is suggestive elevated resistance to blood flow
suggesting obstructive uropathy
Diagnostic Imaging
• Excretory Urography
– Applies anatomic and
functional information
– Limited use in patients
with renal
insufficiency
• Increased risk of
contrast-induced
nephropathy
– Cannot use in patients
with contrast allergy
Diagnostic Imaging
• Whitaker Test
– “True pressure” within the pelvis =
Collecting system pressure – intravesicle presure
• Saline or contrast though a percutaneous
needle or nephrostomy tube at a rate of 10mL/
min
• Catheter in bladder to monitor intravesicle
pressure
Normal < 15 cm H2O Indeterminate = 15-22 cm H2O Obstruction > 22 cm H2O
• CT • MRI
– Most accurate study to – Can identify hydro but unable to
diagnose ureteral calculi identify calculi and ureteral
anatomy of unobstructed
– More sensitive to identify systems
cause of obstruction
– Diuretic MRU can demonstrate
– Helpul in surgical planning obstruction
• Especially accurate with
– **Preferred initial imaging strictures or congential
study in those with suspected abnormalities
ureteral obstruction – IV gadopentetate-DTPA allows
functional assessment of
collecting system while providing
anatomic detail
• GFR assessment
• Renal clearance
– Still several limitations in its use
Issues in Patient Management
• Hypertension
– Can be caused by ureteral obstruction
• Especially BUO or obstruction of a solitary
kidney
• Less common with UUO
– Volume-mediated
• Increased ANP with obstruction which
normalizes after drainage
• Decreased plasma renin activity
Issues in Patient Management
• Renal Drainage
– Endourologic or IR procedures allow prompt temporary
and occasionally permanent drainage
• No statistically significant difference in HRQL between the two
techniques
• Patients with extrinsic compression causing obstruction have a
high risk of ureteral stent failure
– 42-56.4 % failure rate at 3 months
– 43% failed within 6 days of placement in one study
– High failure rate at even getting placement(27%)
– Stent diameter did not predict risk of failure
– Ultrasound guided percutaneous drainage should be
initial consideration in pregnant patients
– Percutaneous placement with suspected pyonephrosis
• Large diameter ureteral stents
Issues in Patient Management
Considerations in Surgical Intervention
• Reconstruction
– Endoscopic, open and laparoscopic techniques
should be considered
• Need for nephrectomy?
– Allow 6-8 weeks for adequate drainage
before proceeding
– Nuclear imaging provides accurate
functional information
• < 10% contribution to global renal function is
considered threshold for nephrectomy
Issues in Patient Management
Pain
• Treatment
1. Correct obstructive uropathy
2. Biopsy to exclude malignancy
3. If biopsy is negative, medical therapy is preferred
– Discontinue any offending medications
– Corticosteroids- prednisolone 60mg qod x 2 mos, tapered to 5mg
daily over the next 2 months, then continue 5mg daily for 2 years
– Tamoxifen
Experimental
– Immunotherapy
4. Ureterolysis- if patient not a candidate for medical therapy or if
it fails
- May do open or laparoscopic
- Bilateral treatment is recommended even if unilateral
disease
- To prevent recurrent ureteral involvement bring ureter
intraperitoneal, or wrap in omentum
- Stents can usually be removed 6-8 wks after ureterolysis
Pelvic Lipomatosis
• Rare benign proliferative disease
involving the mature fatty tissues of the
pelvic retroperitoneum
• 18:1 Male to female
• More common in African American men
• Unknown etiology
– Obesity?
– Genetic?
Pelvic Lipomatosis
• Patient Presentation and Diagnosis
– LUTS, Constipation, non-specific pain, HTN
– Physical Exam- suprapubic mass, high
riding prostate, indistinct pelvic mass
– Younger patients are thought to have a
more progressive course than older
patients who have a more indolent course
Pelvic Lipomatosis
• Imaging
– KUB- Pelvic lucency
– IVP- Bladder is pear-shaped and elevated, hydronephrosis
may be evident
– CT- pelvic fat is readily demonstrated
Pelvic Lipomatosis
• Other evaluation
– Cystoscopy- cystitis cystica, cystitis glandular
(40%), adenocarcinoma, chronic UTI
• High bladder neck, pelvic fixation, and elongated
prostatic urethra may impair rigid cystoscopy
• Treatment
– Exploration is not recommended due to the
obliteration of normal planes and increased
vascularity of the mass
– In patients with obstructive uropathy stents,
PCNs, ureteral reimplanation, urinary diversion
Pregnancy
• Reported to occur in 43-100%
• Right > Left
• Etiology
– Hormonal- progesterone thought to
promote ureteral dilation
– Mechanical – increased degree of dilation
after 20 weeks when the uterus reaches
the pelvic brim
Pregnancy
• Diagnosis
– Usually asymptomatic
• If symptoms, may have flank pain or pyelonephritis
– US will show dilation to the pelvic brim
• If it extends below this, consider other etiologies (stone)
– Limited IVU or MRI to diagnose
• Treatment
– Most respond to conservative treatment
• IVF, analgesics, antibiotics
– If signs of sepsis or compromised renal function
may need ureteral stents or nephrostomy tubes
Endometriosis
• GU involvement
– Bladder 70-80%
– Ureter 15-20%
• May be intrinsic or extrinsic (80%)
• Cyclical flank pain, dysuria, urgency, UTI,
hematuria, or no GU symptoms (silent loss of
renal function may occur)
– Recommended to image the Upper tracts in all
patients with pelvic endometriosis (RUS or EXU)
Endometriosis
• Treatment
– Hormone therapy- if normal renal function
with mild hydro and no functional
obstruction seen on renogram
• GnRH agonists
– Surgery- treatment of choice for patients
with significant disease
• TAH with BSO
• Unilateral oopherectomy
• Ureterolysis if extrinsic disease
• Distal ureterectomy with reimplantation
Vascular Causes of Ureteral Obstruction